Literature DB >> 18780813

Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome.

Kevin R Kozak1, Anand Mahadevan, John S Moody.   

Abstract

The epidemiology and natural history of adult gliosarcomas (GSMs), as well as patient and treatment factors associated with outcome, are ill defined. Patients over 20 years of age with GSM diagnosed from 1988 to 2004 were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier survival analysis and Cox models were used to examine outcomes. Similar analyses were conducted for patients diagnosed with glioblastoma (GBM) over the same time period. GSM represented 2.2% of the 16,388 patients identified with either GSM or GBM. No significant differences between GSM and GBM were identified with respect to age, gender, race, tumor size, or use of adjuvant radiation therapy (RT). Patients with GSM were more likely to have temporal lobe involvement and undergo some form of tumor resection. The most important analyzed factors influencing GSM overall survival were age, extent of resection, and use of adjuvant RT. After adjusting for factors impacting overall survival, the prognosis for GSM appears slightly worse than for GBM (HR = 1.17, 95% CI, 1.05-1.31). GSM is a rare malignancy that presents very similarly to GBM with a slightly greater propensity for temporal lobe involvement. Optimal treatment remains to be defined. However, these retrospective findings suggest tumor excision, as opposed to biopsy only, and adjuvant RT may improve outcome. Despite therapy, prognosis remains dismal and outcomes may be inferior to those seen in GBM patients.

Entities:  

Mesh:

Year:  2008        PMID: 18780813      PMCID: PMC2718990          DOI: 10.1215/15228517-2008-076

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  20 in total

1.  Sarcoma arising in glioblastoma of the brain.

Authors:  I H FEIGIN; S W GROSS
Journal:  Am J Pathol       Date:  1955 Jul-Aug       Impact factor: 4.307

Review 2.  Gliofibroma: mixed glial and mesenchymal tumour. Report of three cases.

Authors:  M C Sharma; S Gaikwad; V S Mehta; J Dhar; C Sarkar
Journal:  Clin Neurol Neurosurg       Date:  1998-06       Impact factor: 1.876

3.  A clinico-pathological study of 29 cases of gliosarcoma with special reference to two unique variants.

Authors:  C Sarkar; M C Sharma; K Sudha; S Gaikwad; A Varma
Journal:  Indian J Med Res       Date:  1997-09       Impact factor: 2.375

4.  Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.

Authors:  E Galanis; J C Buckner; R P Dinapoli; B W Scheithauer; R B Jenkins; C H Wang; J R O'Fallon; G Farr
Journal:  J Neurosurg       Date:  1998-09       Impact factor: 5.115

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Gliosarcomas: analysis of 11 cases do two subtypes exist?

Authors:  Maurizio Salvati; Emanuela Caroli; Antonino Raco; Felice Giangaspero; Roberto Delfini; Luigi Ferrante
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

7.  Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome.

Authors:  B C Devaux; J R O'Fallon; P J Kelly
Journal:  J Neurosurg       Date:  1993-05       Impact factor: 5.115

8.  Problems in the nosology of desmoplastic tumors of childhood.

Authors:  E J Rushing; L B Rorke; L Sutton
Journal:  Pediatr Neurosurg       Date:  1993 Mar-Apr       Impact factor: 1.162

9.  Clinicopathologic features of primary and postirradiation cerebral gliosarcoma.

Authors:  J R Perry; L C Ang; J M Bilbao; P J Muller
Journal:  Cancer       Date:  1995-06-15       Impact factor: 6.860

Review 10.  Primary cerebral gliosarcoma: report of 17 cases.

Authors:  H C Parekh; D G O'Donovan; R R Sharma; A J Keogh
Journal:  Br J Neurosurg       Date:  1995-04       Impact factor: 1.596

View more
  39 in total

Review 1.  Therapeutic management of gliosarcoma in the temozolomide era.

Authors:  Mary Frances McAleer; Paul D Brown
Journal:  CNS Oncol       Date:  2015-04-23

2.  Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.

Authors:  J Castelli; L Feuvret; Q C Haoming; J Biau; E Jouglar; A Berger; G Truc; F Llamas Gutierrez; X Morandi; P J Le Reste; F Thillays; D Loussouarn; E Nouhaud; G Crehange; D Antoni; E Vauleon; R de Crevoisier; G Noel
Journal:  J Neurooncol       Date:  2016-05-11       Impact factor: 4.130

3.  Gliosarcoma: a clinical and radiological analysis of 48 cases.

Authors:  Xiaoping Yi; Hang Cao; Haiyun Tang; Guanghui Gong; Zhongliang Hu; Weihua Liao; Lunquan Sun; Bihong T Chen; Xuejun Li
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

4.  Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.

Authors:  Guobin Zhang; Shengyue Huang; Junting Zhang; Zhen Wu; Song Lin; Yonggang Wang
Journal:  J Neurooncol       Date:  2016-01-02       Impact factor: 4.130

Review 5.  Primary gliosarcoma with long-survival: report of two cases and review of literature.

Authors:  Zhen Huo; Di Yang; Jie Shen; Yuan Li; Huanwen Wu; Yunxiao Meng; Shuying Zhang; Yufeng Luo; Jinling Cao; Zhiyong Liang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

6.  A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.

Authors:  Patrick Y Wen; David Schiff; Timothy F Cloughesy; Jeffrey J Raizer; John Laterra; Melanie Smitt; Michael Wolf; Kelly S Oliner; Abraham Anderson; Min Zhu; Elwyn Loh; David A Reardon
Journal:  Neuro Oncol       Date:  2011-02-04       Impact factor: 12.300

7.  Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.

Authors:  Deborah R Smith; Cheng-Chia Wu; Heva J Saadatmand; Steven R Isaacson; Simon K Cheng; Michael B Sisti; Jeffrey N Bruce; Sameer A Sheth; Andrew B Lassman; Fabio M Iwamoto; Shih-Hsiu Wang; Peter Canoll; Guy M McKhann; Tony J C Wang
Journal:  J Neurooncol       Date:  2017-12-20       Impact factor: 4.130

Review 8.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

9.  Radiotherapy plus concomitant temozolomide in primary gliosarcoma.

Authors:  Sebastian Adeberg; Denise Bernhardt; Semi Ben Harrabi; Christian Diehl; Christian Koelsche; Stefan Rieken; Andreas Unterberg; Andreas von Deimling; Juergen Debus
Journal:  J Neurooncol       Date:  2016-03-30       Impact factor: 4.130

10.  The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.

Authors:  Yuan Zhang; Jun-Peng Ma; Jian-Cong Weng; Liang Wang; Zhen Wu; Da Li; Jun-Ting Zhang
Journal:  Neurosurg Rev       Date:  2020-03-18       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.